Biocon has reported a strong start to FY27, with consolidated total income rising 9% year-on-year to Rs 4,391 crore in the first quarter ended June 30, 2026, powered by robust growth in its Biopharma business.

 

The Bengaluru-based global biopharmaceuticals company posted consolidated operating revenue of Rs 4,336 crore, up 10% from Rs 3,942 crore in Q1FY26. EBITDA stood at Rs 902 crore, with margins holding steady at 21%, as improved profitability in Biopharma helped offset continued pressure in the Services business.

 

Net profit before exceptional items rose sharply to Rs 145 crore, while reported net profit jumped to Rs 141 crore, compared with Rs 31 crore in the same quarter last year.

 

Biocon’s Biopharma business emerged as the key growth engine, with revenue climbing 17% year-on-year to Rs 3,615 crore. Biosimilars revenue increased 16% to Rs 2,855 crore, while Generics revenue grew 21% to Rs 760 crore.

 

The company attributed the momentum to recent biosimilar and generic product launches across major markets, including the United States. The Services business, however, continued to face challenges, with revenue declining 16% year-on-year to Rs 736 crore.

 

Interest costs fell 23% to Rs 213 crore from Rs 277 crore a year ago, following measures taken to strengthen the company’s balance sheet.

 

“Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. 

 

"We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

 

Biocon CEO and Managing Director Shreehas Tambe highlighted the company’s recent product launches and regulatory achievements, including the commercialisation of multiple biosimilars and generic products in the U.S. market.

 

“Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya and Aukelso (biosimilar Denosumab), Yesafili (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. 

 

"We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.”

 

Biocon expanded its biosimilar presence across key geographies during the quarter. In North America, growth was supported by recently launched products including Bosaya and Aukelso (biosimilar Denosumab), along with the commercial launch of Yesafili (aflibercept-jbvf) in the U.S. as an interchangeable biosimilar Aflibercept.

 

The company also secured Health Canada’s Notice of Compliance for Yesintek (biosimilar Ustekinumab) autoinjector pen and launched generic Liraglutide in the U.S.

 

In Europe, Biocon commercialised Evfraxy (biosimilar Denosumab) across multiple markets and expanded its oncology portfolio with Abevmy (biosimilar Bevacizumab) launches in Czech Republic and Switzerland.

 

Across emerging markets, the company strengthened market access through product approvals and commercial partnerships, while maintaining leadership in the biosimilar Bevacizumab franchise in Brazil.

 

Meanwhile, Biocon’s research services arm Syngene continued to focus on strengthening its capabilities amid business challenges. New CEO and Managing Director Siddharth Mittal outlined priorities around commercial execution, cost competitiveness and investments in artificial intelligence and scientific innovation.

 

“As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth.

 

"My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.”

 

During the quarter, Syngene signed an MoU with BRIC-Translational Health Science and Technology Institute (THSTI) to collaborate on early and late-phase clinical development, translational research and bioanalytical sciences.